List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
29 April 2025 | By LevitasBio
Join us for a special webinar featuring Young Kim, titled ‘Sample Prep 2.0: A New Paradigm for Biopharma Research’. He will present an overview of the importance of cell sample prep and how challenges of scaling this up faced by biopharma can be addressed using an innovative, label-free approach called…
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Researchers at ETH Zurich in Switzerland have mapped the complex network cells use to repair their genetic material, revealing previously hidden vulnerabilities in cancer cells.
Learn how to simplify the entire DNA template generation workflow, streamlining mRNA therapeutic research.
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
21 March 2025 | By Abzena
Join our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
